+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Biosimilar"

From
From
From
From
Serum-Free Media - Global Strategic Business Report - Product Thumbnail Image

Serum-Free Media - Global Strategic Business Report

  • Report
  • June 2025
  • 74 Pages
  • Global
From
Small-Scale Bioreactors - Global Strategic Business Report - Product Thumbnail Image

Small-Scale Bioreactors - Global Strategic Business Report

  • Report
  • June 2025
  • 73 Pages
  • Global
From
Cell Culture Media - Global Strategic Business Report - Product Thumbnail Image

Cell Culture Media - Global Strategic Business Report

  • Report
  • June 2025
  • 480 Pages
  • Global
From
Microbial API - Global Strategic Business Report - Product Thumbnail Image

Microbial API - Global Strategic Business Report

  • Report
  • June 2025
  • 466 Pages
  • Global
From
Bioprocess Monitoring - Global Strategic Business Report - Product Thumbnail Image

Bioprocess Monitoring - Global Strategic Business Report

  • Report
  • June 2025
  • 170 Pages
  • Global
From
From
Continuous Bioprocessing - Global Strategic Business Report - Product Thumbnail Image

Continuous Bioprocessing - Global Strategic Business Report

  • Report
  • June 2025
  • 553 Pages
  • Global
From
From
Single Use Assemblies - Global Strategic Business Report - Product Thumbnail Image

Single Use Assemblies - Global Strategic Business Report

  • Report
  • June 2025
  • 93 Pages
  • Global
From
From
Upstream Bioprocessing - Global Strategic Business Report - Product Thumbnail Image

Upstream Bioprocessing - Global Strategic Business Report

  • Report
  • June 2025
  • 89 Pages
  • Global
From
Bioprocess Validation - Global Strategic Business Report - Product Thumbnail Image

Bioprocess Validation - Global Strategic Business Report

  • Report
  • June 2025
  • 385 Pages
  • Global
From
From
From
From
Loading Indicator

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers. Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more